What is the official website of Nanopharm Ltd, an Aptar Pharma Company ?

The official website of Nanopharm Ltd, an Aptar Pharma Company is https://nanopharm.co.uk.

What is Nanopharm Ltd, an Aptar Pharma Company's cybersecurity risk score?

Nanopharm Ltd, an Aptar Pharma Company has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Nanopharm Ltd, an Aptar Pharma Company experienced?

According to Rankiteo, Nanopharm Ltd, an Aptar Pharma Company currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Nanopharm Ltd, an Aptar Pharma Company been affected by any supply chain cyber incidents ?

According to Rankiteo, Nanopharm Ltd, an Aptar Pharma Company has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Nanopharm Ltd, an Aptar Pharma Company have SOC 2 Type 1 certification ?

According to Rankiteo, Nanopharm Ltd, an Aptar Pharma Company is not certified under SOC 2 Type 1.

Does Nanopharm Ltd, an Aptar Pharma Company have SOC 2 Type 2 certification ?

According to Rankiteo, Nanopharm Ltd, an Aptar Pharma Company does not hold a SOC 2 Type 2 certification.

Does Nanopharm Ltd, an Aptar Pharma Company comply with GDPR ?

According to Rankiteo, Nanopharm Ltd, an Aptar Pharma Company is not listed as GDPR compliant.

Does Nanopharm Ltd, an Aptar Pharma Company have PCI DSS certification ?

According to Rankiteo, Nanopharm Ltd, an Aptar Pharma Company does not currently maintain PCI DSS compliance.

Does Nanopharm Ltd, an Aptar Pharma Company comply with HIPAA ?

According to Rankiteo, Nanopharm Ltd, an Aptar Pharma Company is not compliant with HIPAA regulations.

Does Nanopharm Ltd, an Aptar Pharma Company have ISO 27001 certification ?

According to Rankiteo,Nanopharm Ltd, an Aptar Pharma Company is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Nanopharm Ltd, an Aptar Pharma Company operate in ?

Nanopharm Ltd, an Aptar Pharma Company operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Nanopharm Ltd, an Aptar Pharma Company have ?

Nanopharm Ltd, an Aptar Pharma Company employs approximately 68 people worldwide.

Does Nanopharm Ltd, an Aptar Pharma Company own any subsidiaries ?

Nanopharm Ltd, an Aptar Pharma Company presently has no subsidiaries across any sectors.

How many LinkedIn followers does Nanopharm Ltd, an Aptar Pharma Company have ?

Nanopharm Ltd, an Aptar Pharma Company's official LinkedIn profile has approximately 4,452 followers.

What is the NAICS classification code for Nanopharm Ltd, an Aptar Pharma Company ?

Nanopharm Ltd, an Aptar Pharma Company is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Nanopharm Ltd, an Aptar Pharma Company have a Crunchbase profile ?

No, Nanopharm Ltd, an Aptar Pharma Company does not have a profile on Crunchbase.

Does Nanopharm Ltd, an Aptar Pharma Company have a LinkedIn profile ?

Yes, Nanopharm Ltd, an Aptar Pharma Company maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/nanopharm-ltd.

How many cybersecurity incidents has Nanopharm Ltd, an Aptar Pharma Company experienced ?

As of October 18, 2026, Rankiteo reports that Nanopharm Ltd, an Aptar Pharma Company has not experienced any cybersecurity incidents.

How many peer or competitor companies does Nanopharm Ltd, an Aptar Pharma Company have ?

Nanopharm Ltd, an Aptar Pharma Company has an estimated 5,773 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

NLAPC

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Nanopharm Ltd, an Aptar Pharma Company Vendor Cyber Rating & Cyber Score

nanopharm.co.uk

Add Your Compliance Badge

Nanopharm was founded to address industry-wide challenges in converting drugs from concept into viable, effective and consistent nasal and orally inhaled drug products. The company has established itself as a leading provider of tailored analytical and formulation support during all phases of drug development of orally inhaled drug products. Our unique processing technology and formulation development tools aid identification of critical material attributes, their relationship with critical processing parameters and drug product functionality.

NLAPC

Nanopharm Ltd, an Aptar Pharma Company CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

NLAPC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for NLAPC

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Nanopharm Ltd, an Aptar Pharma Company in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Nanopharm Ltd, an Aptar Pharma Company in 2026.

Incident Types NLAPC vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Nanopharm Ltd, an Aptar Pharma Company in 2026.

Incident History - NLAPC (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Nanopharm Ltd, an Aptar Pharma Company Subsidiaries

NLAPC

Pharmaceutical Manufacturing

Website: https://nanopharm.co.uk

Company Size: 68

AptarPackaging and Containers Manufacturing

FusionPKGPersonal Care Product Manufacturing

Aptar CSP TechnologiesPackaging and Containers Manufacturing

Aptar Digital HealthMedical Equipment Manufacturing

OleenaHealth and Human Services

InsuliaMedical Device

Noble, An Aptar Pharma CompanyPharmaceutical Manufacturing

Gateway Analytical, an Aptar Pharma companyPharmaceutical Manufacturing

Next BreathPharmaceutical Manufacturing

Loading…

Nanopharm Ltd, an Aptar Pharma Company Similar Companies

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Loading…

NEWS

Nanopharm Ltd, an Aptar Pharma Company CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-111865

SUMMARY

A security flaw has been discovered in THU-MIG yoloe up to 40cd606cabdbe2b566d6f14a6b162c89206e9a1b. This affects the function eval of the file ultralytics/nn/autobackend.py of the component AutoBackend Model Loading. The manipulation of the argument imgsz/names/kpt_shape results in improper neutralization of directives in dynamically evaluated code. The attack requires a local approach. The exploit has been released to the public and may be used for attacks. This product does not use versioning. This is why information about affected and unaffected releases are unavailable. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-10-17

Updated

Date2026-10-17

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 1.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-111934

SUMMARY

Coder before 2.34.7 contains an IP spoofing vulnerability in the ExtractRealIPAddress middleware that trusts the leftmost, client-supplied X-Forwarded-For value instead of the client IP appended by a reverse proxy. Attackers can send forged X-Forwarded-For values through appending proxies to bypass per-IP rate limits on login, one-time passcode, and password validation endpoints, enabling brute-force attacks, and to falsify IP addresses recorded in audit logs.

Published

Date2026-10-17

Updated

Date2026-10-17

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N

cvss4

Base Score: 6.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-111933

SUMMARY

Coder before 2.29.17, 2.30.0 before 2.32.7, 2.33.0 before 2.33.8, and 2.34.0 before 2.34.2 contains a user enumeration vulnerability because userpassword.Compare() substitutes a placeholder hash derived from the string "hunter2" when a stored password hash is empty. Unauthenticated attackers can submit logins with the password "hunter2" and distinguish HTTP 403 from 401 responses to enumerate valid accounts and reveal the authentication provider of SSO-only users.

Published

Date2026-10-17

Updated

Date2026-10-17

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 6.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-111932

SUMMARY

Coder before 2.29.17, 2.30.0 before 2.32.7, 2.33.0 before 2.33.8, and 2.34.0 before 2.34.2 contains a stored HTML injection vulnerability because the ApplicationName and LogoURL appearance settings are rendered into HTML output without sufficient escaping. Attackers with the Owner role can store HTML markup in these settings that renders in the Coder dashboard and in SMTP notification emails sent to other deployment users.

Published

Date2026-10-17

Updated

Date2026-10-17

RISK INFORMATION (Score: 3.4)

cvss3

Base Score: 3.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:R/S:C/C:N/I:L/A:N

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:P/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.7

REFERENCES

CVE-2026-111931

SUMMARY

Coder from 2.0.0 before 2.34.8 contains an open redirect vulnerability in handleAPIKeySmuggling that allows attackers to redirect users externally via unsanitized r.URL.Path values. Attackers can craft links on trusted workspace app subdomains with paths beginning with double slashes, which become scheme-relative redirects to attacker sites for phishing.

Published

Date2026-10-17

Updated

Date2026-10-17

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Nanopharm Ltd, an Aptar Pharma Company Vendor Cyber Rating & Cyber Score

NLAPC A.I CyberSecurity Scoring

Nanopharm Ltd, an Aptar Pharma Company CyberSecurity News & History

NLAPC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for NLAPC

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types NLAPC vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - NLAPC (X = Date, Y = Severity)

Nanopharm Ltd, an Aptar Pharma Company Subsidiaries

NLAPC

Nanopharm Ltd, an Aptar Pharma Company Similar Companies

Novartis

Sandoz

Hikma Pharmaceuticals

Glenmark Pharmaceuticals

MSD

Grifols

AUROBINDO PHARMA LTD

AbbVie

Takeda

Nanopharm Ltd, an Aptar Pharma Company CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Nanopharm Ltd, an Aptar Pharma Company CyberSecurity News & History

NLAPC Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for NLAPC

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types NLAPC vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - NLAPC (X = Date, Y = Severity)

Nanopharm Ltd, an Aptar Pharma Company Subsidiaries

NLAPC

Nanopharm Ltd, an Aptar Pharma Company Similar Companies

Novartis

Sandoz

Hikma Pharmaceuticals

Glenmark Pharmaceuticals

MSD

Grifols

AUROBINDO PHARMA LTD

AbbVie

Takeda

Nanopharm Ltd, an Aptar Pharma Company CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo